Progress of targeted therapy for anaplastic lymphoma kinase fusion-positive advanced non-small cell lung cancer / 肿瘤研究与临床
Cancer Research and Clinic
;
(6): 69-73, 2022.
Artigo
em Chinês
| WPRIM
| ID: wpr-934630
ABSTRACT
Due to the high incidence and fatality rate of lung cancer, more and more attention is paid to the treatment model of lung cancer. Non-small cell lung cancer (NSCLC) accounts for about 4/5 of the total number of lung cancer patients, and the combination of anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) is found in 3%-7% of all cases. The treatment is mainly targeted therapy. The known targeted drugs for ALK fusion-positive NSCLC have been studied for the fourth generation, providing patients with a variety of medication options; in particular, the research on the fourth-generation drugs TPX-0131 and NUV-655 has brought new hopes to the majority of third-generation targeted drug-resistant patients. At present, China is also working hard to develop new domestic inhibitors, which will provide new drug options for Chinese patients with ALK-positive advanced NSCLC. This article will review its targeted therapy and the latest research, hoping to provide a reference for targeted drug selection.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Cancer Research and Clinic
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS